Teleflex (TFX) Scheduled to Post Earnings on Thursday

Teleflex (NYSE:TFX) is scheduled to post its quarterly earnings results before the market opens on Thursday, October 31st. Analysts expect Teleflex to post earnings of $3.38 per share for the quarter. Teleflex has set its FY24 guidance at $13.80-14.20 EPS and its FY 2024 guidance at 13.800-14.200 EPS.Investors that are interested in participating in the company’s conference call can do so using this link.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, August 1st. The medical technology company reported $3.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.33 by $0.09. The firm had revenue of $749.70 million during the quarter, compared to analysts’ expectations of $762.98 million. Teleflex had a return on equity of 14.51% and a net margin of 8.76%. The company’s revenue was up .9% on a year-over-year basis. During the same period in the previous year, the firm earned $3.41 earnings per share. On average, analysts expect Teleflex to post $14 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Teleflex Stock Performance

Shares of TFX opened at $236.63 on Tuesday. The firm has a market cap of $11.15 billion, a P/E ratio of 42.48, a PEG ratio of 2.12 and a beta of 1.16. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.44 and a current ratio of 2.58. Teleflex has a twelve month low of $177.63 and a twelve month high of $257.85. The firm’s 50 day moving average price is $241.01 and its two-hundred day moving average price is $223.85.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Stockholders of record on Thursday, August 15th were given a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $1.36 annualized dividend and a dividend yield of 0.57%. Teleflex’s dividend payout ratio is currently 24.42%.

Wall Street Analyst Weigh In

TFX has been the topic of several analyst reports. Royal Bank of Canada boosted their price target on shares of Teleflex from $260.00 to $275.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Truist Financial lifted their price target on Teleflex from $247.00 to $255.00 and gave the stock a “hold” rating in a report on Monday, October 14th. Stephens increased their price target on Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Finally, Piper Sandler raised shares of Teleflex from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $205.00 to $245.00 in a research note on Monday, July 1st. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $268.86.

Insider Buying and Selling

In other Teleflex news, Director Stuart A. Randle sold 2,674 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $238.93, for a total value of $638,898.82. Following the completion of the transaction, the director now directly owns 5,496 shares in the company, valued at approximately $1,313,159.28. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.43% of the stock is currently owned by corporate insiders.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.